* Legend Biotech Corp reported a quarterly adjusted loss of 68 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -34 cents. The mean expectation of fifteen analysts for the quarter was for a loss of 42 cents per share. Wall Street expected results to range from -64 cents to -26 cents per share.
* Revenue rose 66.9% to $160.21 million from a year ago; analysts expected $143.87 million.
* Legend Biotech Corp's reported EPS for the quarter was a loss of 68 cents.
* The company reported a quarterly loss of $125.32 million.
* Legend Biotech Corp shares had fallen by 17.8% this quarter and lost 33.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 5.3% in the last three months.
* In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Legend Biotech Corp is 86.00 This summary was machine generated from LSEG data November 12 at 03:36 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.42 -0.68 Missed
Jun. 30 2024 -0.38 -0.10 Beat
Mar. 31 2024 -0.34 -0.32 Beat
Dec. 31 2023 -0.83 -0.80 Beat
Comments